Kestra Medical secures up to USD 200 million five-year term loan facility with Pharmakon Advisors-managed funds
KMTS•Five-year term loan facility
Kestra Medical Technologies entered a five-year term loan facility with funds managed by Pharmakon Advisors for up to USD 200 million.
USD 75 million was funded at closing, and part of the proceeds was used to retire an existing USD 45 million term loan.
Interest terms and repayment
The facility carries interest-only payments for 48 months, extendable by 12 months on a revenue milestone.
The quarterly interest rate is set at 3-month SOFR + 5.5%, with a 3.25% SOFR floor.
Additional tranches through 2028
Additional tranches total USD 125 million through 2028, including a USD 50 million tranche tied to USD 150 million trailing revenue.
